Serum metabolomic signatures predict clinical outcomes in advanced non-small cell lung cancer treated with pembrolizumab plus platinum-based chemotherapy - Summary - MDSpire
Advertisement
Serum metabolomic signatures predict clinical outcomes in advanced non-small cell lung cancer treated with pembrolizumab plus platinum-based chemotherapy
To determine the correlation between serum metabolite profiles and specific clinical outcomes, such as overall survival and progression-free survival, in advanced NSCLC patients treated with pembrolizumab plus chemotherapy.
Key Findings:
Lower serum levels of branched-chain amino acids (BCAAs) valine and isoleucine were linked to disease progression within 60 days.
Long-term survivors exhibited higher levels of lipids, including total phospholipids and sphingomyelin.
Patients who died during follow-up had elevated inflammatory markers like glycoprotein acetyls.
An RF model achieved high accuracy (AUC = 0.93) in predicting survival status, with key contributors being sphingomyelin, apolipoprotein A2, and glycoprotein acetyls B.
Interpretation:
Serum metabolomic profiles can serve as non-invasive biomarkers for predicting clinical outcomes in advanced NSCLC patients undergoing pembrolizumab and chemotherapy.
Limitations:
The study's sample size was relatively small with only 36 patients, which may limit the statistical power and generalizability of the findings.
Findings may not be generalizable to all NSCLC patient populations due to specific inclusion criteria, particularly the exclusion of patients with certain genetic mutations.
Conclusion:
Serum metabolomic profiling reveals significant associations with clinical outcomes in advanced NSCLC, highlighting the potential of specific metabolites as biomarkers for treatment response.
by Peter May, Christof Winter, Inga Hubrecht, Adrian Patenge, Selina Strathmeyer, Roland Geyer, Steffen Heelemann, Jan Stratmann, Seyer Safi, Henriette Klein, Folker Schneller, Florian Bassermann, Aaron Becker von Rose
